by | Jun 15, 2024 | Publications
Br J Cancer. 2024 Jun 14. doi: 10.1038/s41416-024-02742-3. Online ahead of print. ABSTRACT BACKGROUND: Targeting DNA damage repair factors, such as DNA-dependent protein kinase catalytic subunit (DNA-PKcs), may offer an opportunity for effective treatment of multiple...
by | Jun 15, 2024 | Publications
Discov Oncol. 2024 Jun 15;15(1):229. doi: 10.1007/s12672-024-01090-1. ABSTRACT Multiple myeloma (MM) denotes a cancerous growth characterized by abnormal proliferation of plasma cells. Growing evidence suggests that the complexity in addressing MM lies in the presence...
by | Jun 15, 2024 | Publications
Mol Med. 2024 Jun 14;30(1):86. doi: 10.1186/s10020-024-00860-5. ABSTRACT BACKGROUND: Despite the advances of therapies, multiple myeloma (MM) remains an incurable hematological cancer that most patients experience relapse. Tumor angiogenesis is strongly correlated...
by | Jun 14, 2024 | Publications
Blood Adv. 2024 Jun 13:bloodadvances.2023012464. doi: 10.1182/bloodadvances.2023012464. Online ahead of print. ABSTRACT Exosomes have emerged as promising vehicles for delivering therapeutic cargoes to specific cells or tissues, owing to their superior...
by | Jun 14, 2024 | Publications
Am Soc Clin Oncol Educ Book. 2024 Jun;44(3):e432204. doi: 10.1200/EDBK_432204. ABSTRACT Multiple chimeric antigen receptor (CAR) T-cell and bispecific antibody (bsAb) therapies have been approved, demonstrating impressive clinical efficacy in relapsed/refractory...
by | Jun 14, 2024 | Publications
Blood. 2024 Jun 14:blood.2023023529. doi: 10.1182/blood.2023023529. Online ahead of print. ABSTRACT The promising results obtained with immunotherapeutic approaches for multiple myeloma (MM) call for a better stratification of patients based on immune components. The...